Biosimilar Drug Market Report

Global Biosimilar Drug Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Feb 25, 2022
  • PAGES：198
  • REPORT CODE：GMM775680
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Biosimilar Drug market report explains the definition, types, applications, major countries, and major players of the Biosimilar Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Amgen

    • Novartis

    • Eli Lilly

    • Biotech Pharma

    • CP Guojian Pharma

    By Type:

    • Injection

    • Tablets

    • Other Types

    By End-User:

    • Ankylosing Spondylitis

    • Tumor

    • Rheumatoid Arthrtis

    • Cardiovascular

    • Other Application

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Biosimilar Drug Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Biosimilar Drug Outlook to 2028- Original Forecasts

    • 2.2 Biosimilar Drug Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Biosimilar Drug Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Biosimilar Drug Market- Recent Developments

    • 6.1 Biosimilar Drug Market News and Developments

    • 6.2 Biosimilar Drug Market Deals Landscape

    7 Biosimilar Drug Raw Materials and Cost Structure Analysis

    • 7.1 Biosimilar Drug Key Raw Materials

    • 7.2 Biosimilar Drug Price Trend of Key Raw Materials

    • 7.3 Biosimilar Drug Key Suppliers of Raw Materials

    • 7.4 Biosimilar Drug Market Concentration Rate of Raw Materials

    • 7.5 Biosimilar Drug Cost Structure Analysis

      • 7.5.1 Biosimilar Drug Raw Materials Analysis

      • 7.5.2 Biosimilar Drug Labor Cost Analysis

      • 7.5.3 Biosimilar Drug Manufacturing Expenses Analysis

    8 Global Biosimilar Drug Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Biosimilar Drug Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Biosimilar Drug Export by Region (Top 10 Countries) (2017-2028)

    9 Global Biosimilar Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Biosimilar Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Injection Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Tablets Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Other Types Consumption and Growth Rate (2017-2022)

    • 9.2 Global Biosimilar Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Ankylosing Spondylitis Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Tumor Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Rheumatoid Arthrtis Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Cardiovascular Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Other Application Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Biosimilar Drug Market Analysis and Outlook till 2022

    • 10.1 Global Biosimilar Drug Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Biosimilar Drug Consumption (2017-2022)

      • 10.2.2 Canada Biosimilar Drug Consumption (2017-2022)

      • 10.2.3 Mexico Biosimilar Drug Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Biosimilar Drug Consumption (2017-2022)

      • 10.3.2 UK Biosimilar Drug Consumption (2017-2022)

      • 10.3.3 Spain Biosimilar Drug Consumption (2017-2022)

      • 10.3.4 Belgium Biosimilar Drug Consumption (2017-2022)

      • 10.3.5 France Biosimilar Drug Consumption (2017-2022)

      • 10.3.6 Italy Biosimilar Drug Consumption (2017-2022)

      • 10.3.7 Denmark Biosimilar Drug Consumption (2017-2022)

      • 10.3.8 Finland Biosimilar Drug Consumption (2017-2022)

      • 10.3.9 Norway Biosimilar Drug Consumption (2017-2022)

      • 10.3.10 Sweden Biosimilar Drug Consumption (2017-2022)

      • 10.3.11 Poland Biosimilar Drug Consumption (2017-2022)

      • 10.3.12 Russia Biosimilar Drug Consumption (2017-2022)

      • 10.3.13 Turkey Biosimilar Drug Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Biosimilar Drug Consumption (2017-2022)

      • 10.4.2 Japan Biosimilar Drug Consumption (2017-2022)

      • 10.4.3 India Biosimilar Drug Consumption (2017-2022)

      • 10.4.4 South Korea Biosimilar Drug Consumption (2017-2022)

      • 10.4.5 Pakistan Biosimilar Drug Consumption (2017-2022)

      • 10.4.6 Bangladesh Biosimilar Drug Consumption (2017-2022)

      • 10.4.7 Indonesia Biosimilar Drug Consumption (2017-2022)

      • 10.4.8 Thailand Biosimilar Drug Consumption (2017-2022)

      • 10.4.9 Singapore Biosimilar Drug Consumption (2017-2022)

      • 10.4.10 Malaysia Biosimilar Drug Consumption (2017-2022)

      • 10.4.11 Philippines Biosimilar Drug Consumption (2017-2022)

      • 10.4.12 Vietnam Biosimilar Drug Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Biosimilar Drug Consumption (2017-2022)

      • 10.5.2 Colombia Biosimilar Drug Consumption (2017-2022)

      • 10.5.3 Chile Biosimilar Drug Consumption (2017-2022)

      • 10.5.4 Argentina Biosimilar Drug Consumption (2017-2022)

      • 10.5.5 Venezuela Biosimilar Drug Consumption (2017-2022)

      • 10.5.6 Peru Biosimilar Drug Consumption (2017-2022)

      • 10.5.7 Puerto Rico Biosimilar Drug Consumption (2017-2022)

      • 10.5.8 Ecuador Biosimilar Drug Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Biosimilar Drug Consumption (2017-2022)

      • 10.6.2 Kuwait Biosimilar Drug Consumption (2017-2022)

      • 10.6.3 Oman Biosimilar Drug Consumption (2017-2022)

      • 10.6.4 Qatar Biosimilar Drug Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Biosimilar Drug Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Biosimilar Drug Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Biosimilar Drug Consumption (2017-2022)

      • 10.7.2 South Africa Biosimilar Drug Consumption (2017-2022)

      • 10.7.3 Egypt Biosimilar Drug Consumption (2017-2022)

      • 10.7.4 Algeria Biosimilar Drug Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Biosimilar Drug Consumption (2017-2022)

      • 10.8.2 New Zealand Biosimilar Drug Consumption (2017-2022)

    11 Global Biosimilar Drug Competitive Analysis

    • 11.1 Amgen

      • 11.1.1 Amgen Company Details

      • 11.1.2 Amgen Biosimilar Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Amgen Biosimilar Drug Main Business and Markets Served

      • 11.1.4 Amgen Biosimilar Drug Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Novartis

      • 11.2.1 Novartis Company Details

      • 11.2.2 Novartis Biosimilar Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Novartis Biosimilar Drug Main Business and Markets Served

      • 11.2.4 Novartis Biosimilar Drug Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Eli Lilly

      • 11.3.1 Eli Lilly Company Details

      • 11.3.2 Eli Lilly Biosimilar Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Eli Lilly Biosimilar Drug Main Business and Markets Served

      • 11.3.4 Eli Lilly Biosimilar Drug Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Biotech Pharma

      • 11.4.1 Biotech Pharma Company Details

      • 11.4.2 Biotech Pharma Biosimilar Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Biotech Pharma Biosimilar Drug Main Business and Markets Served

      • 11.4.4 Biotech Pharma Biosimilar Drug Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 CP Guojian Pharma

      • 11.5.1 CP Guojian Pharma Company Details

      • 11.5.2 CP Guojian Pharma Biosimilar Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 CP Guojian Pharma Biosimilar Drug Main Business and Markets Served

      • 11.5.4 CP Guojian Pharma Biosimilar Drug Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    12 Global Biosimilar Drug Market Outlook by Types and Applications to 2028

    • 12.1 Global Biosimilar Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Injection Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Tablets Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Other Types Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Biosimilar Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Ankylosing Spondylitis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Tumor Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Rheumatoid Arthrtis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Cardiovascular Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.5 Global Other Application Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Biosimilar Drug Market Analysis and Outlook to 2028

    • 13.1 Global Biosimilar Drug Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.2.2 Canada Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Biosimilar Drug Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.2 UK Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.3 Spain Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.5 France Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.6 Italy Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.8 Finland Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.9 Norway Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.11 Poland Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.12 Russia Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Biosimilar Drug Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.2 Japan Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.3 India Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Biosimilar Drug Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.5.3 Chile Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.5.6 Peru Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Biosimilar Drug Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.6.3 Oman Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Biosimilar Drug Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Biosimilar Drug Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Biosimilar Drug Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Biosimilar Drug Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Biosimilar Drug

    • Figure of Biosimilar Drug Picture

    • Table Global Biosimilar Drug Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Biosimilar Drug Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Injection Consumption and Growth Rate (2017-2022)

    • Figure Global Tablets Consumption and Growth Rate (2017-2022)

    • Figure Global Other Types Consumption and Growth Rate (2017-2022)

    • Figure Global Ankylosing Spondylitis Consumption and Growth Rate (2017-2022)

    • Figure Global Tumor Consumption and Growth Rate (2017-2022)

    • Figure Global Rheumatoid Arthrtis Consumption and Growth Rate (2017-2022)

    • Figure Global Cardiovascular Consumption and Growth Rate (2017-2022)

    • Figure Global Other Application Consumption and Growth Rate (2017-2022)

    • Figure Global Biosimilar Drug Consumption by Country (2017-2022)

    • Table North America Biosimilar Drug Consumption by Country (2017-2022)

    • Figure United States Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Canada Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Mexico Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Biosimilar Drug Consumption by Country (2017-2022)

    • Figure Germany Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure UK Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Spain Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Belgium Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure France Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Italy Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Denmark Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Finland Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Norway Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Sweden Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Poland Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Russia Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Turkey Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Table APAC Biosimilar Drug Consumption by Country (2017-2022)

    • Figure China Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure India Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Thailand Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Singapore Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Philippines Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Table South America Biosimilar Drug Consumption by Country (2017-2022)

    • Figure Brazil Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Colombia Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Chile Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Argentina Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Peru Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Table GCC Biosimilar Drug Consumption by Country (2017-2022)

    • Figure Bahrain Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Oman Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Qatar Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Table Africa Biosimilar Drug Consumption by Country (2017-2022)

    • Figure Nigeria Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure South Africa Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Egypt Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure Algeria Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Table Oceania Biosimilar Drug Consumption by Country (2017-2022)

    • Figure Australia Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Biosimilar Drug Consumption and Growth Rate (2017-2022)

    • Table Amgen Company Details

    • Table Amgen Biosimilar Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Biosimilar Drug Main Business and Markets Served

    • Table Amgen Biosimilar Drug Product Portfolio

    • Table Novartis Company Details

    • Table Novartis Biosimilar Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Biosimilar Drug Main Business and Markets Served

    • Table Novartis Biosimilar Drug Product Portfolio

    • Table Eli Lilly Company Details

    • Table Eli Lilly Biosimilar Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Biosimilar Drug Main Business and Markets Served

    • Table Eli Lilly Biosimilar Drug Product Portfolio

    • Table Biotech Pharma Company Details

    • Table Biotech Pharma Biosimilar Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biotech Pharma Biosimilar Drug Main Business and Markets Served

    • Table Biotech Pharma Biosimilar Drug Product Portfolio

    • Table CP Guojian Pharma Company Details

    • Table CP Guojian Pharma Biosimilar Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table CP Guojian Pharma Biosimilar Drug Main Business and Markets Served

    • Table CP Guojian Pharma Biosimilar Drug Product Portfolio

    • Figure Global Injection Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Tablets Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Types Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ankylosing Spondylitis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Tumor Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Rheumatoid Arthrtis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cardiovascular Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Application Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Biosimilar Drug Consumption Forecast by Country (2022-2028)

    • Table North America Biosimilar Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Biosimilar Drug Consumption Forecast by Country (2022-2028)

    • Figure Germany Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Biosimilar Drug Consumption Forecast by Country (2022-2028)

    • Figure China Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Biosimilar Drug Consumption Forecast by Country (2022-2028)

    • Figure Brazil Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Biosimilar Drug Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Biosimilar Drug Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Biosimilar Drug Consumption Forecast by Country (2022-2028)

    • Figure Australia Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Biosimilar Drug Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US